N@N

BIOGEN IDEC INC. (NASDAQ:BIIB), Up By 12.88% ($11.33) From $87.940 After BUYINS.NET Report Predicted Stock Would Go Up Due To B

^{Published on 2011-09-15 09:21:07 - WOPRAI}
 

September 15, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, August 23rd 2011 stating that BIOGEN IDEC INC. (NASDAQ:BIIB) was expected to go Up due to the Bullish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/tools/symbol_stats.php?sym=biib

At the time this story was written, BIOGEN IDEC INC. (NASDAQ:BIIB) is Up By $11.33 (12.88%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

BIOGEN IDEC INC. (NASDAQ:BIIB) - Biogen Idec Inc., a biotechnology company, discovers, develops, manufactures, and markets therapeutics in the areas of neurology, immunology, hemophilia, and oncology in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkins Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe plaque psoriasis in adult patients. The companys products under Phase III consist of FAMPYRA, an oral compound that is being developed as a treatment to enhance walking ability in people with MS; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis; Recombinant Factors VIII and IX for the treatment of hemophilia; and GA101, a monoclonal antibody for the treatment of chronic lymphocytic leukemia and NHL. Its Phase I clinical trial products include Anti-LINGO, Baminercept, and Neublastin for neurology, as well as Anti-TWEAK and CD40LFab for immunology; and Phase II clinical trial products comprise Anti-TWEAK and Baminercept for immunology. In addition, the companys preclinical stage products consist of BIIB034 for the treatment of Parkinsons disease; and BART and Gamma Secretase Modulator for Alzheimers disease. It has collaboration agreements with Neurimmune SubOne AG; Genentech, Inc.; UCB, S.A.; Acorda Therapeutics, Inc.; Elan Pharma International, Ltd; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; Vernalis plc; and Amunix, Inc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is based in Weston, Massachusetts.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net